Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 2, 2009, Pages 391-398

  Tsavaris, Nicolas ^a   Lazaris, Andreas ^b   Kosmas, Christos ^c   Gouveris, Panagiotis ^a   Kavantzas, Nikolaos ^b   Kopterides, Petros ^a   Papathomas, Thomas ^b   Arapogiannis, George ^b   Zorzos, Haralambos ^b   Kyriakou, Vassiliki ^b   Patsouris, Efstathios ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c METAXA CANCER HOSPITAL   (Greece)

Author keywords

5 FU; Chemotherapy; Colorectal cancer; Topoisomerase I; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); FLUOROURACIL; FOLINIC ACID; ANTINEOPLASTIC ANTIMETABOLITE; DNA; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADJUVANT CHEMOTHERAPY; CANCER STAGING; COLORECTAL TUMOR; ENZYME IMMUNOASSAY; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PLOIDY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DNA; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; FLUOROURACIL; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PLOIDIES; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 66949178721     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0886-4     Document Type: Article

References (57)

1. M Gupta A Fujimori Y Pommier 1995 Eukaryotic DNA topoisomerases I Biochim Biophys Acta 1262 1 14
2. Y Pommier P Pourquier Y Fan D Strumberg 1998 Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme Biochim Biophys Acta 1400 83 105
3. L Stewart MR Redinbo X Qiu WG Hol JJ Champoux 1998 A model for the mechanism of human topoisomerase I Science 279 1534 1541 (Pubitemid 28217077)
4. A Merino KR Madden WS Lane JJ Champoux D Reinberg 1993 DNA topoisomerase I is involved in both repression and activation of transcription Nature 365 227 232
5. SR Florell JF Martinchick JA Holden 1996 Purification of DNA topoisomerase I from the spleen of a patient with non-Hodgkin's lymphoma Anticancer Res 16 3467 3474 (Pubitemid 27084999)
6. DA Burden N Osheroff 1998 Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme Biochim Biophys Acta 1400 139 154 (Pubitemid 28475100)
7. U Kellner A Jacobsen A Kellner R Mantke A Roessner C Röcken 2003 Comparative genomic hybridization. Synchronous occurrence of focal nodular hyperplasia and hepatocellular carcinoma in the same liver is not based on common chromosomal aberrations Am J Clin Pathol 119 265 271 (Pubitemid 37047883)
8. L Nakopoulou A Zervas AC Lazaris C Constantinides C Stravodimos P Davaris C Dimopoulos 2001 Predictive value of topoisomerase IIα immunostaining in urothelial bladder carcinoma J Clin Pathol 54 309 313 (Pubitemid 32270015)
9. D Gibbons F Fogt J Kasznica J Holden S Nikulasson 1997 Comparison of topoisomerase II alpha and Ki-67 expression in uterine cervical squamous lesions Mod Pathol 10 409 413 (Pubitemid 27244225)
10. MM Heck WN Hittelman WC Earnshaw 1988 Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle Proc Natl Acad Sci USA 85 1086 1090 (Pubitemid 18073961)
11. IB Bronstein S Vorobyev A Timofeev CJ Jolles SL Alder JA Holden 1996 Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies Oncol Res 8 17 25 (Pubitemid 26107683)
12. JA Holden MP Rahn CJ Jolles SV Vorobyev IB Bronstein 1997 Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinoma J Clin Pathol 50 247 253 (Pubitemid 27475774)
13. A Boonsong S Curran JA McKay J Cassidy GI Murray HL McLeod 2002 Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases Hum Pathol 33 1114 1119 (Pubitemid 35416709)
14. BE Staley WS Samowitz IB Bronstein JA Holden 1999 Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon Mod Pathol 12 356 361 (Pubitemid 29203324)
15. A Paradiso J Xu A Mangia A Chiriatti G Simone A Zito S Montemurro F Giuliani E Maiello G Colucci 2004 Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients Int J Cancer 111 252 258 (Pubitemid 38924703)
16. LW Coleman SL Perkins IB Bronstein JA Holden 2000 Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas Hum Pathol 31 728 733 (Pubitemid 30445477)
17. KA Monnin IB Bronstein DK Gaffney JA Holden 1999 Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression Hum Pathol 4 384 391 (Pubitemid 29177816)
18. D Gupta IB Bronstein JA Holden 2000 Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival Hum Pathol 31 214 219 (Pubitemid 30090651)
19. P Perego G Capranico R Supino F Zunino 1994 Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types Anticancer Drugs 5 645 649 (Pubitemid 24381882)
20. LW Coleman IB Bronstein JA Holden 2001 Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas Anticancer Res 21 1167 1172 (Pubitemid 32494225)
21. LW Coleman LR Rohr IB Bronstein JA Holden 2002 Human DNA topoisomerase I: an anticancer drug target present in human sarcomas Hum Pathol 33 599 607 (Pubitemid 34827540)
22. BJ Lynch IB Bronstein JA Holden 2001 Elevations of DNA topoisomerase I in invasive carcinoma of the breast Breast J 7 176 180 (Pubitemid 32619779)
23. H Hafian L Venteo A Sukhanova I Nabiev B Lefevre M Pluot 2004 Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas Hum Pathol 35 745 751 (Pubitemid 38881086)
24. AA Shamaa MM Zyada MM Wagner SS Awad MM Osman AA Abdel Azeem 2008 The significance of Epstein Barr Virus (EBV) & DNA topoisomerase IIu (DNA-TopoII) immunoreactivity in normal oral mucosa, oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC) Diagn Pathol 3 45 [Epub ahead of print]
25. C Heidelberger NK Chaudhuri P Danneberg D Mooren L Griesbach R Duschinsky RJ Schnitzer E Pleven J Scheiner 1957 Fluorinated pyrimidines: a new class of tumor inhibitory compounds Nature 179 663 666
26. Libutti SK, Salz LB, Rustgi AK, Tepper JE (2005) Cancer of the colon. In: Devita VT, Hellman S, Rosenberg S (eds) Cancer: principles and practice of oncology, Chap 29, Sect 8. Lippincott Williams and Wilkins, Philadelphia
27. P Gouveris AC Lazaris TG Papathomas A Nonni V Kyriakou J Delladetsima ES Patsouris N Tsavaris 2007 Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy J Cancer Res Clin Oncol 133 1011 1015 (Pubitemid 47561716)
28. AC Lazaris NG Kavantzas HS Zorzos NV Tsavaris PS Davaris 2002 Markers of drug resistance in relapsing colon cancer J Cancer Res Clin Oncol 128 114 118
29. HS Zorzos AC Lazaris PA Korkolopoulou NG Kavantzas S Tseleni-Balafouta ES Patsouris NV Tsavaris PS Davaris 2003 Multidrug resistance proteins and topoisomerase II alpha expression in colon cancer: association with metastatic potential Pathology 35 315 318 (Pubitemid 37082889)
30. N Tsavaris C Kosmas H Zorzos A Lazaris M Vadiaka A Dimitrakopoulos MP Siakantaris S Rokana E Papalambros GA Pangalis P Davaris 2004 Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer Oncol Rep 11 899 903
31. W Ichikawa H Uetake Z Nihei K Mastuo H Fujita Y Yamada 1999 Topoisomerase I (Topo-I) expression correlates to thymidylate synthase (TS) expression in colorectal cancer (CRC) Proc Am Soc Clin Oncol 18 946 (abstract)
32. CG Leichman HJ Lenz L Leichman K Danenberg J Baranda S Groshen W Boswell R Metzger M Tan PV Danenberg 1997 Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin J Clin Oncol 15 3223 3229 (Pubitemid 27419335)
33. KR Hande 1998 Clinical applications of anticancer drugs targeted to topoisomerase II Biochim Biophys Acta 1400 173 184 (Pubitemid 28475102)
34. MJ Luzzio JM Besterman DL Emerson MG Evans K Lackey PL Leitner G McIntyre B Morton PL Myers M Peel JM Sisco DD Sternbach 1995 Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I J Med Chem 38 395 401
35. H Bleiberg 1998 Continuing the fight against advanced colorectal cancer: new and future treatment options Anticancer Drugs 9 18 28 (Pubitemid 28088175)
36. AM Wilstermann RP Bender M Godfrey S Choi C Anklin DB Berkowitz N Osheroff DE Graves 2007 Topoisomerase II-drug interaction domains: identification of substituents on etoposide that interact with the enzyme Biochemistry 46 8217 8225 (Pubitemid 47075961)
37. C Bognel C Rekacewicz H Mankarios JP Pignon D Elias P Duvillard M Prade M Ducreux J Kac P Rougier F Eschwège P Lasser 1995 Prognostic value of neural invasion in rectal carcinoma: a multivariate analysis on 339 patients with curative resection Eur J Cancer 31A 894 898
38. ML Rothenberg HA Burris III 1994 Irinotecan as second line therapy for patients with 5-FU refractory colorectal cancer Proc Am Soc Clin Oncol 13 198 (abstr)
39. JA Conti L Saltz 1994 Irinotecan is an active agent in untreated patients with metastatic colorectal cancer Proc Am Soc Clin Oncol 13 195 (abstr)
40. HC Pitot MJ O'Connell 1994 A phase II trial of CPT-11 in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group Study Proc Am Soc Clin Oncol 13 197 (abstr)
41. E Gupta TM Lestingi R Mick J Ramirez EE Vokes MJ Ratain 1994 Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea Cancer Res 54 3723 3725 (Pubitemid 24241187)
42. N Tsavaris C Kosmas H Skopelitis N Papadoniou A Polyzos G Zografos E Adoniou J Gryniatsos E Felekouras M Zacharakis F Sigala C Bacoyiannis 2007 Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study Chemotherapy 53 282 291 (Pubitemid 47074652)
43. C Gennatas G Papaxoinis V Michalaki D Mouratidou C Andreadis N Tsavaris A Pafiti 2006 A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma J Chemother 18 538 544 (Pubitemid 44776167)
44. N Tsavaris N Ziras C Kosmas T Giannakakis P Gouveris M Vadiaka A Dimitrakopoulos D Karadima S Rokana E Papalambros G Papastratis H Margaris 2003 Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study Cancer Chemother Pharmacol 52 514 519 (Pubitemid 37491643)
45. NB Tsavaris A Polyzos K Gennatas Ch Kosmas M Vadiaka A Dimitrakopoulos A Macheras G Papastratis H Tsipras H Margaris E Papalambros A Giannopoulos 2002 Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination Chemotherapy 48 94 99 (Pubitemid 34507602)
46. Mitry E, Ducreux M, Rougier P (1998) Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials. Bull Cancer 38-42
47. Van Cutsem E, Peeters M (1998) Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials. Bull Cancer 33-7
48. Boige V, Raymond E, Armand JP (1998) Irinotecan: various administration schedules, study of drug combinations, phase I experience. Bull Cancer 26-32
49. AS Planting ME van der Burg MJ van den Bent M de Boer-Dennert G Stoter J Verweij 1996 Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer Br J Cancer 73 1265 1267 (Pubitemid 26162344)
50. R Passalacqua G Bisagni G Cocconi C Boni B Di Blasio G Ceci 1991 Cisplatin and etoposide in advanced colorectal carcinoma Ann Oncol 2 687 688
51. M Posner CA Slapak MJ Browne JW Clark G Curt A Weitberg P Calabresi FJ Cummings M Wiemann S Urba 1990 A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal cancer Am J Clin Oncol 13 455 458 (Pubitemid 20344527)
52. G Colucci E Maiello F Giuliani RA Cifarelli F Giotta 1995 Carboplatin and etoposide in previously treated colorectal cancer patients Tumori 81 36 38
53. RS Zelkowitz MR Posner F Cummings J Beitz AB Weitberg 1989 A phase I/II trial of 5-fluorouracil and etoposide in metastatic colorectal carcinoma Am J Clin Oncol 12 492 493
54. M Inaba J Mitsuhashi S Kawada H Nakano 1994 Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis Jpn J Cancer Res 85 187 193 (Pubitemid 24074545)
55. K Stuart M Posner K Campbell M Huberman 1995 Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma Am J Clin Oncol 18 300 302
56. N Tsavaris C Kosmas K Gennatas M Vadiaka E Skopelitis V Xila S Rokana E Margaris G Zografos G Papastratis G Kouraklis 2002 Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU + LV pre-treated patients with advanced colorectal cancer J Chemother 14 406 411 (Pubitemid 34988933)
57. N Tsavaris C Kosmas K Gennatas M Vadiaka P Paliaros A Dimitrakopoulos T Diamantis H Tsipras G Papastratis 2002 Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer Med Sci Monit 8 65 69